T. Rowe Price Associates
EOLS icon

T. Rowe Price Associates’s Evolus EOLS Stock Holding History

T. Rowe Price Associates’s Portfolio EOLS Stock Details EOLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$403K Buy
97,964
+12,600
+15% +$61.1K ﹤0.01% 2542
2025
Q4 		$568K Buy
85,364
+22,029
+35% +$149K ﹤0.01% 2333
2025
Q3 		$389K Buy
63,335
+7,012
+12% +$54.7K ﹤0.01% 2477
2025
Q2 		$519K Buy
56,323
+1,694
+3% +$17.3K ﹤0.01% 2281
2025
Q1 		$658K Buy
54,629
+2,036
+4% +$26.6K ﹤0.01% 2148
2024
Q4 		$581K Buy
52,593
+6,332
+14% +$89K ﹤0.01% 2227
2024
Q3 		$750K Buy
46,261
+647
+1% +$9.04K ﹤0.01% 2083
2024
Q2 		$495K Buy
45,614
+5,732
+14% +$70.5K ﹤0.01% 2191
2024
Q1 		$559K Buy
39,882
+1,637
+4% +$21.3K ﹤0.01% 2165
2023
Q4 		$403K Buy
38,245
+852
+2% +$7.62K ﹤0.01% 2267
2023
Q3 		$342K Buy
37,393
+791
+2% +$7.09K ﹤0.01% 2287
2023
Q2 		$267K Buy
36,602
+1,834
+5% +$15.8K ﹤0.01% 2416
2023
Q1 		$295K Buy
34,768
+708
+2% +$6.4K ﹤0.01% 2350
2022
Q4 		$256K Buy
34,060
+526
+2% +$4.07K ﹤0.01% 2438
2022
Q3 		$270K Buy
33,534
+7,823
+30% +$82.9K ﹤0.01% 2426
2022
Q2 		$298K Sell
25,711
-7,924
-24% -$93.5K ﹤0.01% 2442
2022
Q1 		$377K Sell
33,635
-8,110
-19% -$69.1K ﹤0.01% 2459
2021
Q4 		$272K Buy
41,745
+18,300
+78% +$126K ﹤0.01% 2633
2021
Q3 		$179K Sell
23,445
-3,600
-13% -$37.2K ﹤0.01% 2750
2021
Q2 		$342K Sell
27,045
-14,739
-35% -$162K ﹤0.01% 2540
2021
Q1 		$543K Buy
+41,784
New +$385K ﹤0.01% 2326

Other funds holding EOLS

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates's EOLS Position: Q1 2026 in Review

T. Rowe Price Associates increased its Evolus (EOLS) stake by 15% in Q1 2026, buying an estimated $61.1K and bringing the position to 97,964 shares worth $403K. The position accounts for ﹤0.01% of the portfolio, ranked #2542.

T. Rowe Price Associates first reported a position in EOLS in Q1 2021 and has held it in 21 quarters since. The position peaked at $750K in Q3 2024. 147 funds tracked by Wall St. Rank hold EOLS as of Q1 2026.

  • T. Rowe Price Associates held 97,964 shares of Evolus worth $403K as of Q1 2026.
  • T. Rowe Price Associates bought 12,600 Evolus shares in Q1 2026, an estimated $61.1K.
  • Evolus made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2542 holding.
  • T. Rowe Price Associates first reported a position in Evolus in Q1 2021 and has held it in 21 quarters since.
  • T. Rowe Price Associates's Evolus position peaked at $750K in Q3 2024.
  • 147 funds tracked by Wall St. Rank held Evolus as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.